Skip to main content

Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites.

Publication ,  Journal Article
Wolfson, JA; Bhatia, S; Ginsberg, JP; Becker, L; Bernstein, D; Henk, HJ; Lyman, GH; Nathan, PC; Puccetti, D; Wilkes, JJ; Winestone, LE; Kenzik, KM
Published in: Cancer Epidemiol Biomarkers Prev
January 2022

BACKGROUND: Outcomes among Hodgkin lymphoma (HL) patients diagnosed between 22 and 39 years are worse than among those diagnosed <21 years, and have not seen the same improvement over time. Treatment at an NCI-designated Comprehensive Cancer Center (CCC) mitigates outcome disparities, but may be associated with higher expenditures. METHODS: We examined cancer-related expenditures among 22- to 39-year-old HL patients diagnosed between 2001 and 2016 using deidentified administrative claims data (OptumLabs Data Warehouse; CCC: n = 1,154; non-CCC: n = 643). Adjusting for sociodemographics, clinical characteristics, and months enrolled, multivariable general linear models modeled average monthly health-plan paid (HPP) expenditures, and incidence rate ratios compared CCC/non-CCC monthly visit rates. RESULTS: In the year following diagnosis, CCC patients had higher HPP expenditures ($12,869 vs. $10,688, P = 0.001), driven by higher monthly rates of CCC nontreatment outpatient hospital visits (P = 0.001) and per-visit expenditures for outpatient hospital chemotherapy ($632 vs. $259); higher CCC inpatient expenditures ($1,813 vs. $1,091, P = 0.001) were driven by 3.1 times higher rates of chemotherapy admissions (P = 0.001). Out-of-pocket expenditures were comparable (P = 0.3). CONCLUSIONS: Young adults with HL at CCCs saw higher health-plan expenditures, but comparable out-of-pocket expenditures. Drivers of CCC expenditures included outpatient hospital utilization (monthly rates of non-therapy visits and per-visit expenditures for chemotherapy). IMPACT: Higher HPP expenditures at CCCs in the year following HL diagnosis likely reflect differences in facility structure and comprehensive care. For young adults, it is plausible to consider incentivizing CCC care to achieve superior outcomes while developing approaches to achieve long-term savings.

Duke Scholars

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

January 2022

Volume

31

Issue

1

Start / End Page

142 / 149

Location

United States

Related Subject Headings

  • Young Adult
  • Humans
  • Hospitalization
  • Hodgkin Disease
  • Health Expenditures
  • Epidemiology
  • Adult
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wolfson, J. A., Bhatia, S., Ginsberg, J. P., Becker, L., Bernstein, D., Henk, H. J., … Kenzik, K. M. (2022). Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites. Cancer Epidemiol Biomarkers Prev, 31(1), 142–149. https://doi.org/10.1158/1055-9965.EPI-21-0321
Wolfson, Julie A., Smita Bhatia, Jill P. Ginsberg, Laura Becker, David Bernstein, Henry J. Henk, Gary H. Lyman, et al. “Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites.Cancer Epidemiol Biomarkers Prev 31, no. 1 (January 2022): 142–49. https://doi.org/10.1158/1055-9965.EPI-21-0321.
Wolfson JA, Bhatia S, Ginsberg JP, Becker L, Bernstein D, Henk HJ, et al. Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites. Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):142–9.
Wolfson, Julie A., et al. “Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites.Cancer Epidemiol Biomarkers Prev, vol. 31, no. 1, Jan. 2022, pp. 142–49. Pubmed, doi:10.1158/1055-9965.EPI-21-0321.
Wolfson JA, Bhatia S, Ginsberg JP, Becker L, Bernstein D, Henk HJ, Lyman GH, Nathan PC, Puccetti D, Wilkes JJ, Winestone LE, Kenzik KM. Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites. Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):142–149.

Published In

Cancer Epidemiol Biomarkers Prev

DOI

EISSN

1538-7755

Publication Date

January 2022

Volume

31

Issue

1

Start / End Page

142 / 149

Location

United States

Related Subject Headings

  • Young Adult
  • Humans
  • Hospitalization
  • Hodgkin Disease
  • Health Expenditures
  • Epidemiology
  • Adult
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences